Lilly director Marschall S. Runge to retire from board effective Aug. 31, 2024

ELI LILLY & Co

Runge served on board since 2013; retirement effective Aug. 31, 2024.
No replacement named; departure not due to any disagreement with company.
Runge also retiring as CEO of Michigan Medicine effective June 30, 2025; will remain on faculty.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Marschall S. Runge

Director

LLY · ELI LILLY & Co

Effective: 2024-08-31
Filed: August 16, 2024, 7:59 PM ET

On August 13, 2024, Dr. Marschall S. Runge notified the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") of his decision to retire from the Board, effective as of August 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marschall S. Runge retired as Director at ELI LILLY & Co.

Action: retired
Role: Director

Exact text from the filing

On August 13, 2024, Dr. Marschall S. Runge notified the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") of his decision to retire from the Board, effective as of August 31, 2024.

View on SEC.gov

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-24-000196

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.